This article examines post-market drug safety, highlighting surveillance mechanisms, regulatory responses, and case studies of approved drugs with hidden risks.

The AI in pharmacovigilance market is expected to grow at a CAGR of 12–15% from 2023 to 2030, driven by the need to automate ...

ELIQUENT Life Sciences (ELIQUENT), a global regulatory, quality, and safety consulting firm, today announced the acquisition of Truliant Consulting ...

Carina Birt, Sarum Life Sciences Limited • Biologit for Local Literature™ delivers results 15 x faster than traditional searches, and is considerably more accurate and reliable • The new ...

Pentagon says Guam could be 1st target of Chinese missiles during Taiwan invasion ...

Gokaraju Rangaraju College of Pharmacy, Hyderabad, has launched its second batch of the free five-day "Upskilling and ...

The drugs are Metronidazole, an antibiotic; Luliconazole, an antifungal; Dalteparin, used for cancer treatment; diabetics ...

A new study from Queen Mary University of London found that 9% of all reported adverse drug reactions (ADRs) reported to the ...

Researchers find new drug associations with floppy iris syndrome, including alpha-1 blockers, atypical antipsychotics, ...

Intraoperative floppy iris syndrome is associated with an increased rate of severe intraoperative complications and greater ...